CD274 and cancer: CTLA-4 and PD-1/PD-L1 are the two best-studied co-inhibitory pathways (97); the use of antibodies as immune checkpoint inhibitors, anti-CTLA4 antibodies, and anti-PD-1/PD-L1 antibodies has been approved for the treatment of several cancers (98–100).